Skip to main content
WST logo

WST · West Pharmaceutical Services Inc · Documents

Track WST — free
Market Cap
$29.01B
Shares
69.66M
Volume · Nov 16 106.26K Avg daily vol (3M) 601.93K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

2024
Oct 24
Quarterly report 10-Q FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Revenue $746.9M ▼ 0.1% Net income $136M ▼ 15.7% Diluted EPS $1.85 ▼ 13.6%
Jul 25
Quarterly report 10-Q FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Revenue $702.1M ▼ 6.9% Net income $111.3M ▼ 28.2% Diluted EPS $1.51 ▼ 26.7%
Apr 25
Quarterly report 10-Q FY2024 Q1, ended Mar 31
Quarterly report for FY2024 Q1
Revenue $695.4M ▼ 3.0% Net income $115.3M ▼ 17.6% Diluted EPS $1.55 ▼ 16.2%
Feb 20
Annual report 10-K FY2023, ended Dec 31
Annual report for FY2023
Revenue $2.95B ▲ 2.2% Net income $593.4M ▲ 1.3% Diluted EPS $7.88 ▲ 1.9%
2023
Oct 26
Quarterly report 10-Q FY2023 Q3, ended Sep 30
Quarterly report for FY2023 Q3
Revenue $747.4M ▲ 8.8% Net income $161.3M ▲ 33.7% Diluted EPS $2.14 ▲ 34.6%
Jul 27
Quarterly report 10-Q FY2023 Q2, ended Jun 30
Quarterly report for FY2023 Q2
Revenue $753.8M ▼ 2.3% Net income $155.1M ▼ 17.7% Diluted EPS $2.06 ▼ 16.9%
Apr 27
Quarterly report 10-Q FY2023 Q1, ended Mar 31
Quarterly report for FY2023 Q1
Revenue $716.6M ▼ 0.5% Net income $140M ▼ 19.4% Diluted EPS $1.85 ▼ 19.2%
Feb 21
Annual report 10-K FY2022, ended Dec 31
Annual report for FY2022
Revenue $2.89B ▲ 2.0% Net income $585.9M ▼ 11.5% Diluted EPS $7.73 ▼ 10.8%
2022
Oct 27
Quarterly report 10-Q FY2022 Q3, ended Sep 30
Quarterly report for FY2022 Q3
Revenue $686.9M ▼ 2.8% Net income $120.6M ▼ 31.3% Diluted EPS $1.59 ▼ 31.2%
Jul 28
Quarterly report 10-Q FY2022 Q2, ended Jun 30
Quarterly report for FY2022 Q2
Revenue $771.3M ▲ 6.6% Net income $188.5M ▲ 0.6% Diluted EPS $2.48 ▲ 0.4%
Apr 28
Quarterly report 10-Q FY2022 Q1, ended Mar 31
Quarterly report for FY2022 Q1
Revenue $720M ▲ 7.4% Net income $173.8M ▲ 14.9% Diluted EPS $2.29 ▲ 15.1%
Showing 51–100 of 146 documents
Key facts CIK 105770 CUSIP 955306105 13F (30d) 681 filings 624 filers Visit website Investor relations